当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Ulrich Kutschera
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and behavioral changes. There are currently no known treatments or medications for AD. Nitric oxide (NO) has long been regarded as a component of the neurotoxic insult brought on by Alzheimer's disease neuroinflammation.
However, this perception is being altered by focusing on early developments, prior to the onset of cognitive symptoms. This has brought to light NO's compensatory, neuroprotective function, which increases neuronal excitability to safeguard synapses. Modulation of voltage-gated potassium channel activity (Kv7 and Kv2) is one potential mechanism by which NO can increase excitability. An important next step for the field is to determine the ionic mechanisms and signaling pathways that mediate this protection. A potential therapeutic option for preventing synapse loss early in disease could be found by harnessing the protective function of NO and related signaling pathways.